ABSTRACT – A previously healthy 20-year-old female presented with extensive retiform purpura located at the face, upper and lower limbs, one week after an episode of acute tonsillitis. Despite the exuberance of the cutaneous findings and progression to skin necrosis she had no accompanying symptoms. Laboratory investigation revealed a heterozygous protein C mutation (exon 9, c.1332G> C, p.Trp444Cys), accounting for a partial deficiency of this anticoagulant protein. The patient was started on broad spectrum antibiotics, anticoagulation and systemic corticosteroids, with no lesional progression and complete resolution of cutaneous ulceration within 6 months. This is a singular case of purpura fulminans, since two different causative factors precipitated the events. The previous tonsillitis reported by the patient is significant, because the serum concentration of protein S may also decrease after an infectious event - post-infectious purpura fulminans. This case illustrates that purpura fulminans due to autoantibodies against protein S, although rare, should be considered, especially in the absence of a severe acute infection. It also illustrates how in a given patient different independent factors can act simultaneously, triggering potentially devastating clinical scenarios.

KEYWORDS – Protein C Deficiency; Protein S; Purpura Fulminans.
prothrombin time and activated partial thromboplastin time were normal). Inflammatory laboratory parameters were low or negative, including C-reactive protein and procalcitonin. The search for occult septic foci was negative. Antistreptolysin O titre and antinuclear antibodies were negative.

Additionally, skin biopsy revealed thrombotic occlusion of the dermal vessels, without associated inflammatory infiltrate (Fig. 3).

In light of the described findings at admittance - purpura fulminans of unknown etiology with rapid progression - the patient was started on broad spectrum antibiotics (meropenem), anticoagulation with enoxaparin (80 mg twice daily) and systemic corticosteroids (1 g methylprednisolone IV for 3 days with subsequent tapering).

Only days later, did the patient mention that in her family a direct cousin had suffered a leg amputation as a newborn, because of a “blood clotting problem”. Further genetic study revealed a heterozygous protein C mutation (exon 9, c.1332G>C, p.Trp444Cys), resulting in a partial protein C deficiency (functional protein C of 65%).

The remaining pro-thrombotic study revealed no other findings (including antiphospholipid antibodies, factor V of Leiden, homocysteine and cryoglobulins). Unfortunately, dosing of autoantibodies against protein S was unavailable and, therefore, not performed.

With the aforementioned treatment, progression of purpura and skin necrosis stopped. The patient required prolonged local care with dressings but overall had a favorable clinical evolution, with complete recovery after six months. After 8 months, enoxaparin was replaced by warfarin, that she keeps until today (target INR range 2.0 – 3.0). Three-years after these events she remains well, with no further thrombotic events.

**DISCUSSION**

Purpura fulminans is a rare clinical emergency that occurs in a context of disseminated intravascular coagulation as a result of increased expression of procoagulant factors associated with the depletion of natural anticoagulants. It should be noted, however, that purpura fulminans is not an independent entity, and may occur in a multiplicity of clinical scenarios (more commonly induced by sepsis or by warfarin treatment, but also associated with inherited protein C deficits). Mortality and morbidity in the setting of purpura fulminans are high, commonly leading to limb amputations. Prompt diagnosis and readily treatment are crucial.

Protein C is a vitamin K-dependent serine protease that constitutes a major natural anticoagulant. Protein C deficits can be acquired, namely due to consumption during sepsis or during the onset of warfarin,
in this case due to a transient imbalance between protein C and procoagulant factors that are synthesized with different timelines under the dependence the same cofactor, vitamin K. Inherited homozygous mutations or compound heterozygous mutations represent a rare cause of protein C deficiency, which usually presents in the neonatal period, leading to limb amputations, as occurred in this patients’ cousin, or to death if left untreated.1,2 On the other hand, heterozygous mutations lead only to partial deficiencies, that alone are not associated with clinical manifestations. Thus, in this particular case, other causative factors must be implicated, namely the infectious episode reported 7 days earlier. This is noteworthy because in post-infectious purpura fulminans the serum concentration of protein S may decrease after an infectious event due to the production of antibodies during the infection that can bind and inhibit protein S function,3 but unhappily this test was not available among us and serum values of protein S showed no significant change during the course of the disease.

Post-infectious purpura fulminans is rare and develops during the recovery period from group A streptococcal infection, varicella–zoster, or rarely, from human herpesvirus 6 infection.3,4

Postinfectious purpura fulminans begins 7 to 10 days after the onset of the initial infection and correlates with the production of infection-triggered antibodies to protein S.4,5 As protein S is a co-factor of protein C during anti-coagulation this could explain the exuberance of the clinical findings in a patient with a partial protein C deficiency.

This case draws attention to purpura fulminans, a rare clinical emergency which requires immediate treatment to prevent mortality and long-lasting morbidity. Although sepsis is the most frequent etiology, it is important to bear in mind other rarer causes. In addition, the case stands out for its rarity and striking presentation.

**REFERENCES**


